INTRODUCTION
============

The overall 5-year survival associated with gastric cancer in India has been estimated to be between 4% and 15% \[[@B1][@B2]\]. This is less than that reported from most Western countries and other Asian countries \[[@B3]\]. Available data on operable, potentially curable gastric cancers in India is sparse. This has been highlighted by Sharma et al*.* \[[@B4]\] who also report the need for robust cancer survival data. The disease presentation and results of operable gastric cancer therapy differ among American, European, and Asian countries. Therefore, extrapolating international findings without any available Indian data would be speculative. We present our experience of treating operable, non-metastatic gastric cancer over a 9-year period. To our knowledge, this is the largest reported series from India.

MATERIALS AND METHODS
=====================

The study was conducted in a dedicated upper gastrointestinal (GI) unit of a tertiary care teaching hospital in South India after obtaining the Institutional Review Board (IRB) clearance (Approval No. 10204). The study was performed in accordance with ethical principles for medical research as outlined in the Declaration of Helsinki. Data for patients who underwent subtotal or total gastrectomy for operable, non-metastatic gastric cancer between January 2006 and December 2014 were retrospectively studied. Electronic hospital records were used to collect data on clinical parameters, histopathological staging, and the type of surgery. Follow-up and survival data were collected from telephonic interviews, electronic mails, and electronic hospital records. Patients with gastro-esophageal junction tumors and palliative gastric resections were excluded from the study.

As per the protocol, all patients underwent pre-operative cross-sectional imaging (i.e. computed tomography \[CT\] of the abdomen) and upper GI endoscopy for tumor visualization and biopsy for histological confirmation. Operability was assessed based on the pre-operative contrast enhanced CT results and cases of all patients were discussed during the upper GI multi-disciplinary tumor board meeting. A diagnostic laparoscopy was performed prior to performing definitive surgery from the year 2010.

The surgical procedures performed included a radical total or subtotal gastrectomy depending on the location of the primary tumor. If the tumor infiltrated an adjacent organ, a multi-visceral resection was performed, provided that an R0 resection was possible. A D1+ or a D2 lymphadenectomy was performed in the majority of our patients \[[@B5]\].

Histopathological staging was done using the tumor, node, metastasis (TNM) classification as defined by the American Joint Committee on Cancer (AJCC), 7th edition \[[@B6]\]. Following the surgical treatment, cases of all patients were re-discussed during the upper GI multidisciplinary tumor board meeting and the plan for adjuvant therapy was finalized. Patients who were at a disease stage \>T2, N0 were administered adjuvant therapy. The adjuvant therapy included 5-fluorouracil and cisplatin in the initial study period (2004--2010). However, since 2011, oxaliplatin, docetaxel, and oral capecitabine are used. Administration of perioperative (neoadjuvant) chemotherapy was commenced in 2014; therefore, only eight patients in the study group fell into this category. In this series, the majority of patients underwent upfront surgery followed by adjuvant chemotherapy/chemo radiotherapy. The type of therapy was tailored according to the stage of the disease, general condition of the patient, and the logistic difficulties faced by patients in view of the long travelling distances to avail treatment.

The patients were followed up in the surgical outpatient and the medical/radiation oncology outpatient clinics on a regular basis. Anastomotic leak was diagnosed as any clinical or radiological leak of GI contents.

Data were analyzed using SPSS for Windows (version 16.0; SPSS Inc., Chicago, IL, USA). Statistical significance for individual variables was analyzed using the χ^2^ and Fisher\'s exact test for categorical variables and t-test for continuous variables. Survival analysis was performed using Kaplan-Meier curves and compared using log rank (Mantel-Cox) test. The number at risk analysis was assessed using StataCorp, 2013 (Stata Statistical Software: Release 13; StataCorp LP software, College Station, TX, USA).

RESULTS
=======

Four hundred and twenty-seven patients underwent gastric resections for operable, non-metastatic gastric cancer. Subtotal gastrectomy with Roux-en-Y gastrojejunostomy was performed in 291 patients and total gastrectomy with Roux-en-Y oesophagojejunostomy was performed in 136 patients.

The mean age of patients with gastric cancer was 52 years (range 23--84 years). The baseline demographics of patients in the study cohort are presented in [Table 1](#T1){ref-type="table"}.

###### Baseline demographics of patients with operable non-metastatic gastric cancer
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  Variables                        No. (%)                            
  -------------------------------- ---------------------------------- ------------
  Age (yr)                                                            
                                   ≤50                                169 (39.6)
                                   \>50                               258 (60.4)
  Sex                                                                 
                                   Male                               301 (70.4)
                                   Female                             126 (29.6)
  BMI (kg/m**^2^**)                                                   
                                   \<18.5                             114 (26.7)
                                   18.5--25.0                         244 (57.1)
                                   26.0--30.0                         45 (10.5)
                                   \>30.0                             24 (5.6)
  Comorbid illnesses                                                  
                                   Diabetes mellitus                  70 (16.4)
                                   Hypertension                       66 (15.4)
                                   Ischemic heart disease             25 (5.9)
                                   Chronic kidney/pulmonary disease   24 (5.6)
  ASA score                                                           
                                   1                                  105 (24.6)
                                   2                                  227 (53.2)
                                   3                                  90 (21.0)
                                   4                                  5 (1.2)
  Location of tumor                                                   
                                   Antropyloric region                263 (61.6)
                                   Body                               117 (27.4)
                                   Fundus                             38 (8.9)
                                   Cardia                             6 (1.4)
                                   Diffuse                            3 (0.7)
  Neoadjuvant therapy              8/427 (1.8)                        
  Adjuvant therapy                                                    
                                   Yes                                336 (78.6)
                                   No                                 68 (16.0)
                                   Missing data                       23 (5.4)
  No. of operations in each year                                      
                                   2006                               40
                                   2007                               41
                                   2008                               43
                                   2009                               41
                                   2010                               41
                                   2011                               48
                                   2012                               56
                                   2013                               58
                                   2014                               59

BMI = body mass index; ASA = American Society of Anesthesiologists.

Surgical details such as the extent of lymphadenectomy, R0/R1/R2 resection, multi-organ resection, the length of hospital stays, the details of postoperative complications, early post-operative mortality (within 30 days) are summarized in [Table 2](#T2){ref-type="table"}. Gastrectomy was performed using the open technique in all patients.

###### Surgical characteristics
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  Variables                                        No. (%)                          
  ------------------------------------------------ -------------------------------- ---------------
  Type of surgery                                                                   
                                                   Sub-total gastrectomy            291 (68.1)
                                                   Total gastrectomy                136 (31.9)
  Lymphadenectomy                                                                   
                                                   D0                               36 (8.4)
                                                   D1+                              259 (60.7)
                                                   D2                               124 (29.1)
                                                   Missing                          8 (1.8)
  Resection                                                                         
                                                   R0                               297 (69.6)
                                                   R1                               70 (16.4)
                                                   R2                               60 (14)
  Multivisceral resection (n=22)                                                    
                                                   Spleen                           8
                                                   Distal pancreatico-splenectomy   2
                                                   Liver resection                  3
                                                   Transverse colon                 9
  Post-operative complication (Anastomotic leak)                                    
                                                   Subtotal gastrectomy             20/29 (6.8)
                                                   Total gastrectomy                20/136 (14.7)
  Average hospital stay (day)                                                       
                                                   Subtotal gastrectomy             14
                                                   Total gastrectomy                17
  30-day mortality                                                                  
                                                   Subtotal gastrectomy             11/291 (3.7)
                                                   Total gastrectomy                7/136 (5.1)

A total of 40 patients had local infiltration to the adjacent organs such as the colon (n=9), pancreas (n=19), liver (n=3), and spleen (n=8). Extended multi-visceral resection (when feasible) was performed in 22 patients in our series. En-block colectomy was performed in nine patients, splenectomy in eight, distal pancreatectomy, and splenectomy in 2, while 2 patients underwent segment-3 liver en-block excision. In the cases where extended multi-visceral resection was not feasible, the tumor was grossly dissected off the adjacent organ.

The histopathological characteristics of operable gastric cancers are described in [Table 3](#T3){ref-type="table"}. The most common TNM stage of presentation was stage IIIC.

###### Histopathological demographics
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  Histopathological parameters   No. (%)                     
  ------------------------------ --------------------------- ------------
  Mucinous                       19 (4.4)                    
  Signet ring                    67 (15.7)                   
  Grade of tumor                                             
                                 Well differentiated         12 (2.8)
                                 Moderately differentiated   159 (37.2)
                                 Poorly differentiated       246 (57.7)
                                 Missing                     10 (2.3)
  T stage                                                    
                                 T1                          31 (7.2)
                                 T2                          33 (7.8)
                                 T3                          166 (38.9)
                                 T4a                         157 (36.7)
                                 T4b                         40 (9.4)
  N stage                                                    
                                 N0                          88 (20.6)
                                 N1                          78 (18.2)
                                 N2                          100 (23.4)
                                 N3                          161 (37.8)
  Staging                                                    
                                 Stage I                     43 (10.0)
                                 Stage IIA                   40 (9.4)
                                 Stage IIB                   59 (13.9)
                                 Stage IIIA                  76 (17.8)
                                 Stage IIIB                  96 (22.5)
                                 Stage IIIC                  113 (26.4)
  Mean nodes sampled             13 (SD±7.9)                 
  Lymphovascular invasion        154 (36.1)                  
  Perineural invasion            152 (35.6)                  
  MLR^\*^                                                    
                                 MLR0                        87 (20.3)
                                 MLR1                        77 (18.1)
                                 MLR2                        94 (22.0)
                                 MLR3                        169 (39.6)

SD = standard deviation; MLR = metastatic lymph node ratio.

^\*^MLR is ratio of total lymph nodes with tumor to total lymph nodes harvested---MLR0=0; MLR1\>0--0.3; MLR2\>0.3--0.6; MLR3\>0.6.

Follow-up data were available for 306 patients with a mean follow-up of 34.1 months (median=27 months). The 5-year disease free survival (DFS) and overall survival (OS) were 39.8% and 59.3% across all stages. The 3-year DFS and OS was 50.0% and 67.9%, respectively ([Fig. 1A and B](#F1){ref-type="fig"}).

![Kaplan-Meier curve. (A) DFS; (B) OS.\
DFS = disease free survival; OS = overall survival.](jgc-17-63-g001){#F1}

The stage wise 5-year DFS and OS are shown in [Fig. 2A and B](#F2){ref-type="fig"}. Detailed stage wise 5-year DFS and OS breakup is shown in [Table 4](#T4){ref-type="table"}.

![Kaplan-Meier curve for stage wise. (A) DFS; (B) OS.\
DFS = disease free survival; OS = overall survival; TNM = tumor, node, metastasis.](jgc-17-63-g002){#F2}

###### Stage wise 5-year OS and DFS
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  Staging      5-year OS   5-year DFS
  ------------ ----------- ------------
  Stage I      85.5        82.3
  Stage IIA    78.5        46.5
  Stage IIB    61.5        37.7
  Stage IIIA   51.9        32.2
  Stage IIIB   47.3        19.0
  Stage IIIC   42.9        25.5

OS = overall survival; DFS = disease free survival.

For the univariate analysis, stage of tumor, grade of the tumor, lymphovascular and perineural invasion, metastatic lymph node ratio (MLR; ratio of the positive nodes to total nodes sampled) \[[@B7][@B8][@B9]\], type of resection (R0/R1/R2), adequate lymphadenectomy (15 or more nodes harvested) \[[@B10]\], and grade of tumor were significant poor predictors of OS and DFS ([Tables 5](#T5){ref-type="table"} and [6](#T6){ref-type="table"}). However, for the multi-variable analysis, only stage of the tumor (P=0.049) and MLR (P=0.047) significantly predicted worse 5-year OS. Stage of the tumor (P=0.048) and MLR (P=0.043) significantly predicted the 5-year DFS on multivariable analysis.

###### Factors predicting poor OS on univariate analysis (n=306)
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  Variables                 Total        Deaths   P-value^\*^
  ------------------------- ------------ -------- -------------
  Staging                                         \<0.001
                            Stage I      35       3
                            Stage IIA    32       6
                            Stage IIB    46       9
                            Stage IIIA   53       15
                            Stage IIIB   59       17
                            Stage IIIC   81       31
  Grade                                           0.071
                            Well         6        0
                            Moderate     119      27
                            Poor         181      51
  Lymphovascular invasion                         0.021
                            Yes          104      34
                            No           202      47
  Peri-neural invasion                            0.001
                            Yes          116      41
                            No           190      40
  Signet ring                                     0.991
                            Yes          43       13
                            No           263      68
  Mucinous                                        0.131
                            Yes          14       5
                            No           292      76
  Resection                                       0.011
                            R0           217      52
                            R1           51       16
                            R2           38       13
  D0 vs. D1+ and D2                               0.288
                            D1+/D2       279      71
                            D0           23       10
  Nodes harvested                                 0.607
                            \<15         183      45
                            ≥15          123      36
  MLR                                             \<0.001
                            MLR0         73       12
                            MLR1         52       12
                            MLR2         67       18
                            MLR3         114      39

OS = overall survival; MLR = metastatic lymph node ratio.

^\*^Log rank test.

###### Factors predicting recurrence on univariate analysis (n=306)
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  Variables                 Total        Recurrence   P-value^\*^
  ------------------------- ------------ ------------ -------------
  Staging                                             0.001
                            Stage I      35           4
                            Stage IIA    32           13
                            Stage IIB    46           17
                            Stage IIIA   53           26
                            Stage IIIB   59           35
                            Stage IIIC   81           46
  Grade                                               0.026
                            Well         6            0
                            Moderate     119          49
                            Poor         181          87
  Lymphovascular invasion                             0.026
                            Yes          104          54
                            No           202          86
  Peri-neural invasion                                0.022
                            Yes          116          60
                            No           190          79
  Signet ring                                         0.776
                            Yes          43           23
                            No           263          117
  Mucinous                                            0.181
                            Yes          14           7
                            No           292          133
  Resection                                           0.012
                            R0           217          93
                            R1           51           28
                            R2           38           19
  D0 vs. D1+ and D2                                   0.395
                            D1+/D2       279          124
                            D0           23           13
  Nodes harvested                                     0.042
                            \<15         183          83
                            ≥15          123          58
  MLR                                                 0.001
                            MLR0         73           21
                            MLR1         52           18
                            MLR2         67           34
                            MLR3         114          68

MLR = metastatic lymph node ratio.

^\*^Log rank test.

The majority of patients included in the series were referred from the North-Eastern parts of India (44%); thus, the majority of participants had to travel more than 1,500 kilometers to reach the hospital. As a subset analysis, the demographics, histopathology, and survival were studied based on the patients\' geographical distribution ([Table 7](#T7){ref-type="table"}). Patients from the North-Eastern part of India were 5 years younger than those from the Southern part (P\<0.01). There was no difference in stage wise presentation, location of primary or the long-term survival statistics between patients of different geographical locations treated at our center.

###### Geographical demographics
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  Variables           North-eastern India      South India   Central and North India   P-value
  ------------------- ------------------------ ------------- ------------------------- ---------
  No. of patients     197 (46.1)               184 (43.0)    46 (10.7)                 
  Mean age (yr)       50.5                     55            52.7                      0.010
  Location                                                                             0.634
                      Pyloro-antral            113           121                       29
                      Body                     59            46                        12
                      Fundus                   20            13                        5
                      Cardia                   3             2                         
                      Diffuse gastric cancer   2             2                         0
  Staging                                                                              0.129
                      Stage I                  21            21                        4
                      Stage II                 39            43                        16
                      Stage III                137           120                       26
  Male:female ratio   2.2:1                    2.3:1         2.1:1                     0.150
  5-year OS (%)       66.0                     52.0          59.0                      0.238

OS = overall survival.

DISCUSSION
==========

Gastric cancer is the fifth and seventh most common cancer among Indian men and women, respectively, and the second most common cause of cancer related deaths \[[@B11][@B12]\]. Although multi-modal therapy can improve survival of gastric cancer patients, surgery is generally considered as the only treatment modality that can cure gastric cancer \[[@B13]\]. Most information pertaining to gastric cancer survival in India has been derived from epidemiology based cancer registries. Detailed analysis of prognostic factors and survival analysis of operable non-metastatic gastric cancer from India is however lacking.

The average age of presentation was 52 years, which is about fifteen years lower than reported from American cancer registries and a decade lower than reports from Asia \[[@B14][@B15]\]. Over 2/3 of patients in our series were male patient; the male preponderance is in line with data from the American cancer surveillance database, Surveillance, Epidemiology, and End Results (SEER) \[[@B16]\].

Sixty-one percent of tumors originated in the antro-pyloric region. Other reports from India also suggest distal tumors as more common than proximal tumors \[[@B4]\]. A large population based study from China revealed higher incidence of distal tumors \[[@B17]\]. However, in developed countries, there is a trend towards more proximal tumors \[[@B18]\].

In keeping with other reports from India, the majority of patients in our series presented at an advanced stage (stage III) \[[@B19]\]. A similar trend was seen in other regions where population-based cancer screening is not done such as America, Europe, and China \[[@B17][@B20][@B21]\].

The 5-year OS in our series is higher than from cancer registries in India. However, stage wise survival and DFS data for gastric cancer from India is lacking, thus comparisons are difficult. The Madras, Mumbai, and Bhopal cancer registry estimate the overall 5-year survival of gastric cancer (stage I--IV) at 8.0%, 15.0%, and 3.8%, respectively between 1990 and 2000 \[[@B2][@B22]\].

In comparison with international data, stage adjusted survival of operable gastric cancer from our series is similar to reports from the USA (MD Anderson group) and China. However, the stage adjusted survival data from Japan and South Korea exceed those reported in our series \[[@B17][@B20][@B23][@B24]\].

The subset analysis based on the geographical distribution of patients revealed that the stage wise distribution and location of tumor were comparable between patients referred from various parts of the country. Patients referred from the North-Eastern parts of the country presented 5 years earlier than those from the Southern part; they also had better 5-year DFS and OS. However, this did not translate into statistical significance. The exact reason behind this difference in survival is not known. India has a multi-ethnic population cohort as described by Basu et al*.*\[[@B25]\]. Difference in ethnicity between different populations in India along with different dietary habits may be attributed to this difference in age of presentation and survival. Further detailed studies to verify this observation are warranted.

The factors that predicted worse 5-year DFS and OS were analyzed. Poor tumor biology may be an unmodifiable factor. However, completeness of resection and performing aggressive surgery safely, including multi-visceral resections, may need to be explored given that R0 resection and adequate lymphadenectomy offer better survival rates \[[@B26]\].

There is little consensus on the management of Gastric cancer because of the 'East-West' divide. Over 50% of gastric cancer in a non-screened population such as Europe and America are inoperable or metastatic at presentation. There is a transatlantic divide in the management of gastric cancers. While chemo-radiotherapy is given in a perioperative setting in North America, neoadjuvant chemotherapy is given for locally advanced gastric cancer in the rest of the Western world. In contrast, over 50% of gastric cancers diagnosed in Korea and Japan are early stage and operated upfront irrespective of the stage of diagnosis. The OS is also vastly different between the East and the West (--60% vs. --20%, respectively) \[[@B27]\]. Given this global divide and heterogeneity of presentation, management, and outcomes internationally, it is imperative that Indian data is available to tailor the management of this disease to the Indian patient. This article aims to highlight the Indian experience with operable non-metastatic gastric cancer and to enhance the global perspectives on the long-term outcomes of this disease.

Most patients with operable gastric cancer present at an advanced stage in India. The 5-year DFS and OS of patients with non-metastatic gastric cancer treated at a dedicated upper gastrointestinal center in India is good and comparable with the results for other countries where no population-based screening is performed.

The study limitations are as follows, the study period spanned over 10 years, a period during which surgical technique, adjuvant therapy, and pathological definitions have changed. The mean follow up of 34.1 months is low. A majority of patients travelled more than 1,500 kilometers for therapy and follow-up, making complete and thorough follow-up logistically difficult. Moreover, because the study was performed at a single tertiary care center, a referral bias should be factored in the results.
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